Bolt Biotherapeutics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Fortress Biotech, Inc.

Bolt Biotherapeutics, Inc.

Assembly Biosciences, Inc.

Sol-Gel Technologies Ltd.

Rezolute, Inc.

SELLAS Life Sciences Group, Inc.

MEI Pharma, Inc.

Daré Bioscience, Inc.

Minerva Neurosciences, Inc.

Kineta, Inc.

SciSparc Ltd.

Why is Bolt Biotherapeutics, Inc. ?

OPERATING CASH FLOW(Y) Highest at USD -51.36 MM
OPERATING PROFIT(Q) Highest at USD -8.86 MM
PRE-TAX PROFIT(Q) Highest at USD -8.56 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -57.83%, its profits have risen by 7.1%

High Institutional Holdings at 65.53%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -57.83% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Bolt Biotherapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Bolt Biotherapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Bolt Biotherapeutics, Inc.

-51.87%

0.32

1813.32%

S&P 500

13.09%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

36.56%

EBIT Growth (5y)

-11.37%

EBIT to Interest (avg)

-76.02

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.80

Sales to Capital Employed (avg)

0.09

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

65.53%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.26

EV to EBIT

0.39

EV to EBITDA

0.40

EV to Capital Employed

-2.59

EV to Sales

-6.83

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-125.05%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -51.36 MM

OPERATING PROFIT(Q)

Highest at USD -8.86 MM

PRE-TAX PROFIT(Q)

Highest at USD -8.56 MM

NET PROFIT(Q)

Highest at USD -8.56 MM

RAW MATERIAL COST(Y)

Fallen by -26.28% (YoY

EPS(Q)

Highest at USD -4.46

-13What is not working for the Company

NET SALES(HY)

At USD 3.03 MM has Grown at -53.79%

ROCE(HY)

Lowest at -81.33%

DEBT-EQUITY RATIO (HY)

Highest at -29.27 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.95 times

Here's what is working for Bolt Biotherapeutics, Inc.

Operating Cash Flow

Highest at USD -51.36 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -8.86 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (USD MM)

Pre-Tax Profit

Highest at USD -8.56 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -8.56 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Pre-Tax Profit

At USD -8.56 MM has Grown at 51.44%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -8.56 MM has Grown at 51.44%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -4.46

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -26.28% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Bolt Biotherapeutics, Inc.

Net Sales

At USD 3.03 MM has Grown at -53.79%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Debt-Equity Ratio

Highest at -29.27 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 5.95 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio